Cargando…

Efficacy of a novel avian metapneumovirus live vaccine candidate based on vaccination route and age

This article describes a series of animal studies for the development of an avian metapneumovirus (aMPV) live vaccine. Although aMPV causes continual economic loss in the poultry industry, there are no live aMPV vaccines available in Korea. Furthermore, information is limited with respect to standar...

Descripción completa

Detalles Bibliográficos
Autores principales: Youn, Ha-Na, Noh, Jin-Yong, Kim, Myeong-Seob, Ju, Hyo-Sun, Park, Dam-Hee, Lee, Da-Ye, Kim, Kyu-jik, Go, Seong-Hye, Song, Chang-Seon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7936137/
https://www.ncbi.nlm.nih.gov/pubmed/33518307
http://dx.doi.org/10.1016/j.psj.2020.07.021
_version_ 1783661140171030528
author Youn, Ha-Na
Noh, Jin-Yong
Kim, Myeong-Seob
Ju, Hyo-Sun
Park, Dam-Hee
Lee, Da-Ye
Kim, Kyu-jik
Go, Seong-Hye
Song, Chang-Seon
author_facet Youn, Ha-Na
Noh, Jin-Yong
Kim, Myeong-Seob
Ju, Hyo-Sun
Park, Dam-Hee
Lee, Da-Ye
Kim, Kyu-jik
Go, Seong-Hye
Song, Chang-Seon
author_sort Youn, Ha-Na
collection PubMed
description This article describes a series of animal studies for the development of an avian metapneumovirus (aMPV) live vaccine. Although aMPV causes continual economic loss in the poultry industry, there are no live aMPV vaccines available in Korea. Furthermore, information is limited with respect to standard field practices for vaccinations at an early age. Here, the development of an aMPV live vaccine was attempted, and its efficacy was investigated with respect to the vaccination route and age to develop a method for controlling aMPV. Before vaccine development, an animal challenge model was established using the aMPV field isolate to identify the most effective time and site for collecting samples for evaluation. After attenuation of the virulent aMPV in Vero cells, a safety and efficacy test was conducted for the vaccine candidate. As a novel aMPV live vaccine candidate, aMPV K655/07HP displayed sufficient safety in day-old chicks with 10 vaccine doses. The efficacy test using 1-week-old chicks showed weaker humoral immune response than that in 4-week-old chicks. However, the candidate vaccine provided complete protection against infection caused by the challenge virus for all ages of vaccinated chicks. In conclusion, an effective aMPV challenge model was established for studying aMPV in chickens, which offered important, insightful information. The safety and efficacy study suggested that the new aMPV candidate vaccine could be used to effectively reduce the economic losses incurred because of aMPV infection.
format Online
Article
Text
id pubmed-7936137
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-79361372021-03-15 Efficacy of a novel avian metapneumovirus live vaccine candidate based on vaccination route and age Youn, Ha-Na Noh, Jin-Yong Kim, Myeong-Seob Ju, Hyo-Sun Park, Dam-Hee Lee, Da-Ye Kim, Kyu-jik Go, Seong-Hye Song, Chang-Seon Poult Sci Immunology, Health and Disease This article describes a series of animal studies for the development of an avian metapneumovirus (aMPV) live vaccine. Although aMPV causes continual economic loss in the poultry industry, there are no live aMPV vaccines available in Korea. Furthermore, information is limited with respect to standard field practices for vaccinations at an early age. Here, the development of an aMPV live vaccine was attempted, and its efficacy was investigated with respect to the vaccination route and age to develop a method for controlling aMPV. Before vaccine development, an animal challenge model was established using the aMPV field isolate to identify the most effective time and site for collecting samples for evaluation. After attenuation of the virulent aMPV in Vero cells, a safety and efficacy test was conducted for the vaccine candidate. As a novel aMPV live vaccine candidate, aMPV K655/07HP displayed sufficient safety in day-old chicks with 10 vaccine doses. The efficacy test using 1-week-old chicks showed weaker humoral immune response than that in 4-week-old chicks. However, the candidate vaccine provided complete protection against infection caused by the challenge virus for all ages of vaccinated chicks. In conclusion, an effective aMPV challenge model was established for studying aMPV in chickens, which offered important, insightful information. The safety and efficacy study suggested that the new aMPV candidate vaccine could be used to effectively reduce the economic losses incurred because of aMPV infection. Elsevier 2020-08-07 /pmc/articles/PMC7936137/ /pubmed/33518307 http://dx.doi.org/10.1016/j.psj.2020.07.021 Text en © 2020 The Authors http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Immunology, Health and Disease
Youn, Ha-Na
Noh, Jin-Yong
Kim, Myeong-Seob
Ju, Hyo-Sun
Park, Dam-Hee
Lee, Da-Ye
Kim, Kyu-jik
Go, Seong-Hye
Song, Chang-Seon
Efficacy of a novel avian metapneumovirus live vaccine candidate based on vaccination route and age
title Efficacy of a novel avian metapneumovirus live vaccine candidate based on vaccination route and age
title_full Efficacy of a novel avian metapneumovirus live vaccine candidate based on vaccination route and age
title_fullStr Efficacy of a novel avian metapneumovirus live vaccine candidate based on vaccination route and age
title_full_unstemmed Efficacy of a novel avian metapneumovirus live vaccine candidate based on vaccination route and age
title_short Efficacy of a novel avian metapneumovirus live vaccine candidate based on vaccination route and age
title_sort efficacy of a novel avian metapneumovirus live vaccine candidate based on vaccination route and age
topic Immunology, Health and Disease
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7936137/
https://www.ncbi.nlm.nih.gov/pubmed/33518307
http://dx.doi.org/10.1016/j.psj.2020.07.021
work_keys_str_mv AT younhana efficacyofanovelavianmetapneumoviruslivevaccinecandidatebasedonvaccinationrouteandage
AT nohjinyong efficacyofanovelavianmetapneumoviruslivevaccinecandidatebasedonvaccinationrouteandage
AT kimmyeongseob efficacyofanovelavianmetapneumoviruslivevaccinecandidatebasedonvaccinationrouteandage
AT juhyosun efficacyofanovelavianmetapneumoviruslivevaccinecandidatebasedonvaccinationrouteandage
AT parkdamhee efficacyofanovelavianmetapneumoviruslivevaccinecandidatebasedonvaccinationrouteandage
AT leedaye efficacyofanovelavianmetapneumoviruslivevaccinecandidatebasedonvaccinationrouteandage
AT kimkyujik efficacyofanovelavianmetapneumoviruslivevaccinecandidatebasedonvaccinationrouteandage
AT goseonghye efficacyofanovelavianmetapneumoviruslivevaccinecandidatebasedonvaccinationrouteandage
AT songchangseon efficacyofanovelavianmetapneumoviruslivevaccinecandidatebasedonvaccinationrouteandage